IP Library Patent Application 11341870
Patent Application
App. No. 11/341,870

Multi-component inhibitors of nucleic acid polymerases

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
11/341,870
Abstract

The present invention provides multi-component inhibitors of nucleic acid polymerases, methods of making, and methods of using same. One component of the multi-component inhibitor is a molecule that binds to a polymerase (i.e., a polymerase-binding molecule (PBM)), but does not thereby substantially inhibit its polymerase activity. Another component is a molecule or complex of molecules that binds to a PBM (i.e., a PBM-binding molecule). The combination of the PBM and PBM-binding molecule/complex substantially inhibits polymerase activity.

Claims (36)

1 . A composition comprising:

(a) a nucleic acid polymerase;

(b) a polymerase-binding molecule (PBM) that binds to said polymerase and does not substantially inhibit the polymerase activity of said polymerase; and

(c) a PBM-binding molecule/complex that binds to said PBM, wherein binding of the PBM and PBM-binding molecule or complex together substantially inhibits the polymerase activity of said polymerase.

2 . The composition of claim 1 , wherein said PBM is an antibody (PBA).

3 . The composition of claim 2 , wherein said PBA is a monoclonal antibody.

4 . The composition of claim 1 , wherein said PBM-binding molecule/complex comprises an antibody, protein G, protein A, a derivatized antibody, a derivatized protein G, a derivatized protein A, IgG, a derivatized protein G, sir22, or sibA.

5 . The composition of claim 1 , wherein said PBM-binding molecule/complex comprises a detectable label, protein, or a polymer.

6 - 9 . (canceled)

10 . The composition of claim 3 , wherein said PBM-binding molecule/complex comprises a monoclonal antibody, polyclonal antibody, Fc antibody fragment, chimeric antibody or recombinant antibody.

11 . The composition of claim 10 , wherein said antibody is derivatized with a detectable label, protein, or polymer.

12 - 17 . (canceled)

18 . The composition of claim 1 , wherein said polymerase is thermostable.

19 . (canceled)

20 . The composition of claim 18 , wherein said polymerase is recombinant.

21 . A composition comprising:

(a) a thermostable nucleic acid polymerase;

(b) a polymerase-binding antibody (PBA) that binds to said polymerase and does not substantially inhibit the polymerase activity of said polymerase; and

(c) a PBA-binding molecule/complex that binds to said PBA, wherein binding of the PBA and PBA-binding molecule/complex together substantially inhibits the polymerase activity of said polymerase at a temperature less than about 40° C., and wherein binding of the PBA and PBA-binding molecule/complex together does not substantially inhibit the polymerase activity of said polymerase at a temperature greater than about 40° C.

22 - 23 . (canceled)

24 . The composition of claim 21 , wherein said polymerase is recombinant.

25 . A method of inhibiting the polymerase activity of a nucleic acid polymerase comprising contacting said polymerase with a PBM and a PBM-binding molecule/complex, wherein the binding of said PBM does not substantially inhibit polymerase activity of said polymerase, and wherein the binding of said PBM and said PBM-binding molecule/complex together substantially inhibit the polymerase activity of said polymerase.

26 . The method of claim 25 , wherein said inhibition is reversible.

27 . The method of claim 25 , wherein said inhibition is reversible by heating to a temperature of at least about 40° C.

28 . The method of claim 25 , wherein said PBM is an antibody (PBA).

29 . The method of claim 28 , wherein said PBA is a monoclonal antibody.

30 - 31 . (canceled)

32 . The method of claim 25 , wherein said polymerase is recombinant.

33 . A method for synthesizing a nucleic acid molecule, comprising:

(a) contacting a template nucleic acid with a composition comprising a thermostable nucleic acid polymerase, one or more nucleoside and/or deoxynucleoside triphosphates, a polymerase binding molecule (PBM) that does not substantially inhibit the polymerase activity of the polymerase, and a PBM-binding molecule/complex under conditions where the PBM and the PBM-binding molecule/complex together substantially inhibit the polymerase activity of the polymerase; and

(b) bringing the resulting mixture to a temperature sufficient relieve polymerase inhibition.

34 . The method of claim 33 , wherein said PBM is an antibody (PBA).

35 . The method of claim 34 , wherein said PBA is a monoclonal antibody.

36 . The method of claim 35 , wherein said inhibition is reversible by heating to a temperature of at least about 40° C.

37 - 38 . (canceled)

39 . The method of claim 33 , wherein said nucleic acid polymerase is recombinant.

Assignments (6)
CORRECTIVE ASSIGNMENT TO CORRECT THE APPLICATION NO 09452626 PREVIOUSLY RECORDED ON REEL 023882 FRAME 0551. ASSIGNOR(S) HEREBY CONFIRMS THE MERGER SHOULD NOT HAVE BEEN RECORDED AGAINST THIS PATENT APPLICATION NUMBER. Recorded Nov 14, 2014
From: INVITROGEN CORPORATION
To: LIFE TECHNOLOGIES CORPORATION
Reel/Frame 034217/0490 →
LIEN RELEASE Recorded Apr 9, 2013
From: BANK OF AMERICA, N.A.
To: LIFE TECHNOLOGIES CORPORATION
Reel/Frame 030182/0461 →
MERGER Recorded Feb 3, 2010
From: INVITROGEN CORPORATION
To: LIFE TECHNOLOGIES CORPORATION
Reel/Frame 023882/0551 →
CHANGE OF NAME Recorded Dec 2, 2009
From: INVITROGEN CORPORATION
To: LIFE TECHNOLOGIES CORPORATION
Reel/Frame 023593/0193 →
SECURITY AGREEMENT Recorded Dec 5, 2008
From: LIFE TECHNOLOGIES CORPORATION
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 021975/0467 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 7, 2006
From: BISHOP, JOHN D.; LEE, JUN E.
To: INVITROGEN CORPORATION
Reel/Frame 017740/0164 →